NOTE: this monograph does NOT apply to Hyoscine Butylbromide

1 vial

$1.33

Scopolamine hydrobromide

  • Reduction of respiratory tract and oral secretions (particularly in the palliative setting). Note, for this indication, hyoscine butylbromide is preferred by the palliative care team.

IV:
0.4mg in 1ml (solution)
Room temperature. Protect from light.
Dilute required dose to 10ml with normal saline. Inject slowly over 3-5 minutes.
Compatible with the following IV fluids:
Normal saline 5% Glucose Hartmanns

IM or SC:
Inject undiluted into a large muscle mass or subcutaneously


ADULT DOSE

IV, IM, SC:
0.3-0.6 mg 6-8 hourly

PAEDIATRIC DOSE

IV, IM, SC:
6-8mcg/kg 6-8 hourly

DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY
Dose as in normal renal function

Hyoscine hydrobromide is one of the major antimuscarinic agents that inhibit the action of acetylcholine (ACh) on autonomic effectors innervated by postganglionic cholinergic nerves as well as on smooth muscles that lack cholinergic innervation. It exerts little effects on the actions of ACh at nicotinic receptor sites such as autonomic ganglia.

CONTRAINDICATIONS:

  • Hypersensitivity to hyoscine hydrobromide


WARNINGS
May cause significant sedation

PRECAUTIONS
General
Because of the tachycardic effects of the drugs, care must be exercised when tachycardia, other tachyarrhythmias, coronary heart disease, congestive heart disease or hyperthyroidism preexist.

Laboratory Tests
No tests in addition to routine ICU tests are required

Drug/Laboratory Test Interactions
None known

Other drugs, such as phenothiazines, tricyclic antidepressants, certain antihistamines, which have weak antimuscarinic activity, may considerably intensify the effects of antimuscarinic drugs.

Body as a Whole:
Suppression of sweating causes reflexive flushing and heat intolerance
Nervous System:
Sedation, confusion, hallucinations
Cardiovascular
Hypotension, tachycardia
Gastrointestinal
Dry mouth
Urogenital:
Urinary Retention

[an error occurred while processing this directive]